Gilead Sciences, Inc. (NASDAQ:GILD) research-based biopharmaceutical firm, is reporting third quarter earnings results on Wednesday 28th October 2020, after market close.
The consensus estimates from Thomson Reuters are income of $ 1.95 per share.
For the full year, analysts predict revenues of $ 24171.90 million, while looking forward to income of $ 6.98 per share.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 23,000.00 million ~ $ 25,000.00 million, where as bottomline are predicted in a range of $ 6.25 ~ $ 7.65 per share
Click Here For More Historical Outlooks Of Gilead Sciences, Inc.
Previous Quarter Performance
Gilead Sciences, Inc. reported income for the second quarter of $ 1.11 per share, from the revenue of $ 5,143.00 million. The quarterly earnings 39.01 percent while revenues down 9.53 percent compared with the same quarter last year.
According to street consensus, GILD was expected to report 2Q20 income of $ 1.45 per share from revenue of $ 5305.03 million. The bottom line results missed street analysts by $ 0.34 or 23.45 percent, at the same time, top line results fell short of analysts by $ 162.03 million or 3.05 percent.
Stock Performance
Shares of Gilead Sciences, Inc. traded up $ 0.05 or 0.08 percent on Tuesday, reaching $ 60.01 with volume of 7.70 million shares. Gilead Sciences, Inc. has traded high as $ 60.21 and has cracked $ 59.44 on the downward trend
According to the previous trading day, closing price of $ 60.01, representing a 0.94 % increase from the 52 week low of $ 59.40 and a 30.25 % decrease over the 52 week high of $ 85.97.
The company has a market capital of $ 75.24 billion and is part of the Healthcare sector and Drug Manufacturers – Major industry.
Recent Analyst recommendations
- On 18th September 2020, maintained by RBC Capital at Outperform rating, with $ 86.00 target price.
- On 15th September 2020, upgraded by Maxim Group to Buy from Hold rating.
- On 15th September 2020, maintained by RBC Capital at Outperform rating, with $ 82.00 target price.
- On 14th September 2020, maintained by SVB Leerink at Outperform rating, with $ 88.00 target price.
- On 10th September 2020, maintained by Oppenheimer at Outperform rating, with $ 105.00 target price.
Recent Stock Dividend Announcement
On July 30, 2020, the board of directors authorized quarterly dividend of $ 0.68 per share to holders of record as of the close of business on September 15, 2020, with payment date of September 29, 2020 and ex-dividend date on September 14, 2020.
Conference Call
Gilead Sciences, Inc. will be hosting a conference call at 4:30 PM eastern time on 28th October 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.gilead.com
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The companys products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases. It also provides Yescarta, a chimeric antigen receptor T cell therapy for adult patients with relapsed or refractory large B-cell lymphoma; Zydelig, a kinase inhibitor; Letairis, an oral formulation of an endothelin receptor antagonist for pulmonary arterial hypertension; Ranexa, a tablet to treat chronic angina; and AmBisome, an antifungal agent to treat serious invasive fungal infections.
